Critical to prioritize cardiovascular disease as a key factor in the management of type 2 diabetes, study says

24 September 2020

Danish diabetes giant Novo Nordisk (NOV: N) has announced the results of the CAPTURE study.

The global non-interventional study seeks to uncover the prevalence of cardiovascular disease and risk and its management in people living with type 2 diabetes.

It is also the first study of its kind and involves nearly 10,000 participants from 13 countries across five continents. Results show that one in three people with type 2 diabetes have established cardiovascular disease, and nine in 10 of these had atherosclerotic cardiovascular disease.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK